Pieter van der Meer

Pieter van der Meer joined Gilde in 1998 following a consultant position with KPMG Management Consulting in the Netherlands. At KPMG, Pieter was involved with due diligence and strategic projects within various sectors. Pieter van der Meer was a member of the Working Group of the Dutch Participation Association (NVP), advising the Ministry of Economic Affairs on policy to stimulate early stage venture creation. He is a member of the project screening committees at Dutch Universities. He holds a master degree in Chemistry from Leiden University, specializing in bio-organic synthesis and molecular modeling. Pieter van der Meer is a Dutch national and speaks English and Spanish. He led investments in Ablynx, Acacia Pharma, Agendia, Inpharmatica and BG Medicine. He represented Gilde on the board of Ablynx and is currently on the boards of Acacia Pharma, Agendia and BG Medicine.